@article{article, title  = {{Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial}},

 publisher = {{Elsevier BV}},

 url = {{http://dx.doi.org/10.1016/s1470-2045(22)00793-8 }},

 year = {{2023}},

 month = {{2}},

 author = {{Brown JE and Royle K-L and Gregory W and Ralph C and Maraveyas A and Din O and Eisen T and Nathan P and Powles T and Griffiths R and Jones R et al}},

 doi = {{10.1016/s1470-2045(22)00793-8}},

 volume = {{24}},

 journal = {{The Lancet Oncology}},

 issue = {{3}},

 pages = {{213-227}},

 note = {{Accessed on 2024/12/21}}}